Resmed (RSMDF) Common Equity (2010 - 2026)

Resmed (RSMDF) has reported Common Equity for 17 consecutive years, with $6.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 10.35% year-over-year to $6.6 billion; the trailing twelve-month figure through Jun 2026 stood at $6.6 billion (up 10.35% YoY), and the FY2026 full-year result was $6.6 billion, up 10.35% from the prior year.
• Common Equity rose to $6.6 billion in Q2 2026 per RSMDF's latest filing, from $6.5 billion in the prior quarter.
• Across five years, Common Equity topped out at $6.6 billion in Q2 2026 and bottomed at $3.3 billion in Q1 2022.
• Historically, Common Equity has averaged $4.9 billion across 5 years, with a median of $4.7 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Common Equity rose 23.81% in 2023, then grew 10.35% in 2026.
• Over 5 years, Common Equity stood at $3.7 billion in 2022, then advanced by 19.9% to $4.5 billion in 2023, then advanced by 17.21% to $5.3 billion in 2024, then climbed by 20.33% to $6.3 billion in 2025, then advanced by 4.18% to $6.6 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $6.6 billion, $6.5 billion, and $6.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.